NTLA Intellia Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NTLA

Price (delayed)

$39.84

Market cap

$3.51B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.16

Enterprise value

$3.11B

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. ...

Highlights
The gross profit has soared by 58% YoY
The company's quick ratio has surged by 58% YoY and by 49% QoQ
The company's debt has surged by 77% YoY and by 34% QoQ
The net income has plunged by 77% YoY and by 7% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.intelliatx.com/
Peers: OVID

Key stats

What are the main financial stats of NTLA
Market
Shares outstanding
88.02M
Market cap
$3.51B
Enterprise value
$3.11B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.54
Price to sales (P/S)
58.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
59.74
Earnings
Revenue
$52.12M
EBIT
-$474.19M
EBITDA
-$466.61M
Free cash flow
-$346.7M
Per share
EPS
-$6.16
Free cash flow per share
-$4.5
Book value per share
$15.7
Revenue per share
$0.68
TBVPS
$19.75
Balance sheet
Total assets
$1.52B
Total liabilities
$284.53M
Debt
$130.7M
Equity
$1.24B
Working capital
$1.09B
Liquidity
Debt to equity
0.11
Current ratio
9.61
Quick ratio
9.45
Net debt/EBITDA
0.84
Margins
EBITDA margin
-895.3%
Gross margin
100%
Net margin
-909.8%
Operating margin
-879%
Efficiency
Return on assets
-38.6%
Return on equity
-48.7%
Return on invested capital
-49.5%
Return on capital employed
-34%
Return on sales
-909.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NTLA stock price

How has the Intellia Therapeutics stock price performed over time
Intraday
-1.75%
1 week
11.22%
1 month
-1.34%
1 year
-42.3%
YTD
14.19%
QTD
14.19%

Financial performance

How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$52.12M
Gross profit
$52.12M
Operating income
-$458.16M
Net income
-$474.19M
Gross margin
100%
Net margin
-909.8%
The net income has plunged by 77% YoY and by 7% from the previous quarter
The company's operating income has shrunk by 71% YoY and by 7% QoQ
The gross profit has soared by 58% YoY
Intellia Therapeutics's revenue has surged by 58% YoY

Growth

What is Intellia Therapeutics's growth rate over time

Valuation

What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
2.54
P/S
58.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
59.74
The EPS has plunged by 63% YoY and by 4.8% from the previous quarter
The stock's P/B is 53% below its 5-year quarterly average of 5.4 and 42% below its last 4 quarters average of 4.4
Intellia Therapeutics's equity has increased by 50% from the previous quarter and by 19% YoY
Intellia Therapeutics's revenue has surged by 58% YoY
The price to sales (P/S) is 35% lower than the last 4 quarters average of 91.1 and 30% lower than the 5-year quarterly average of 83.6

Efficiency

How efficient is Intellia Therapeutics business performance
Intellia Therapeutics's ROIC has decreased by 49% YoY and by 11% from the previous quarter
The ROA has contracted by 45% YoY and by 2.4% from the previous quarter
Intellia Therapeutics's ROE has decreased by 45% YoY
The ROS has contracted by 12% YoY and by 6% from the previous quarter

Dividends

What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NTLA.

Financial health

How did Intellia Therapeutics financials performed over time
The company's quick ratio has surged by 58% YoY and by 49% QoQ
NTLA's current ratio has surged by 57% year-on-year and by 47% since the previous quarter
The company's debt is 89% lower than its equity
The company's debt has surged by 77% YoY and by 34% QoQ
The debt to equity has soared by 57% YoY but it has contracted by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.